{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:01:17Z","timestamp":1772020877443,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 72074047"],"award-info":[{"award-number":["Grant No. 72074047"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40271-025-00776-0","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:16:07Z","timestamp":1762323367000},"page":"329-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eliciting Patient-Centric Value Parameters: A National Best-Worst Scaling Profile Case Survey for Second-Line Antidiabetic Drugs in China"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2650-9357","authenticated-orcid":false,"given":"Dai","family":"Lian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6878-6272","authenticated-orcid":false,"given":"Shimeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-0748","authenticated-orcid":false,"given":"Yingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"4","key":"776_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrendo.2011.183","volume":"8","author":"L Chen","year":"2012","unstructured":"Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus\u2014present and future perspectives. Nat Rev Endocrinol. 2012;8(4):228\u201336.","journal-title":"Nat Rev Endocrinol"},{"issue":"24","key":"776_CR2","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1001\/jama.2021.22208","volume":"326","author":"LM Wang","year":"2021","unstructured":"Wang LM, Peng W, Zhao ZP, Zhang M, Shi ZM, Song ZW, et al. Prevalence and treatment of diabetes in China, 2013\u20132018. JAMA. 2021;326(24):2498\u2013506.","journal-title":"JAMA"},{"key":"776_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100700","author":"J Liu","year":"2023","unstructured":"Liu J, Liu M, Chai Z, Li C, Wang Y, Shen M, et al. Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030. Lancet Reg Health West Pac. 2023. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100700.","journal-title":"Lancet Reg Health West Pac"},{"issue":"4","key":"776_CR4","first-page":"311","volume":"37","author":"Chinese Diabetes Society","year":"2021","unstructured":"Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Endocrinol Metab. 2021;37(4):311\u201398.","journal-title":"Chin J Endocrinol Metab"},{"issue":"23","key":"776_CR5","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","volume":"384","author":"M Fang","year":"2021","unstructured":"Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in US adults, 1999\u20132018. N Engl J Med. 2021;384(23):2219\u201328.","journal-title":"N Engl J Med"},{"issue":"Supplement_2","key":"776_CR6","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.2337\/dcS13-2011","volume":"36","author":"RA DeFronzo","year":"2013","unstructured":"DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Supplement_2):S127\u201338.","journal-title":"Diabetes Care"},{"key":"776_CR7","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetic Association","year":"2021","unstructured":"American Diabetic Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S111\u201324.","journal-title":"Diabetes Care"},{"issue":"10","key":"776_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.7326\/M20-2470","volume":"173","author":"K Doyle-Delgado","year":"2020","unstructured":"Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association\u2019s standards of medical care in diabetes clinical guideline. Ann Intern Med. 2020;173(10):813.","journal-title":"Ann Intern Med"},{"issue":"7","key":"776_CR9","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2337\/dc13-2527","volume":"37","author":"TS Purnell","year":"2014","unstructured":"Purnell TS, Joy S, Little E, Bridges JFP, Maruthur N. Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care. 2014;37(7):2055\u201362.","journal-title":"Diabetes Care"},{"key":"776_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/JMDH.S122383","volume":"10","author":"C Marzorati","year":"2017","unstructured":"Marzorati C, Pravettoni G. Value as the key concept in the health care system: how it has influenced medical practice and clinical decision-making processes. J Multidiscip Healthc. 2017;10:101\u20136.","journal-title":"J Multidiscip Healthc"},{"key":"776_CR11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/PPA.S106821","volume":"10","author":"WH Polonsky","year":"2016","unstructured":"Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adher. 2016;10:1299\u2013307.","journal-title":"Patient Prefer Adher"},{"issue":"1","key":"776_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40271-020-00450-7","volume":"14","author":"NL Crossnohere","year":"2021","unstructured":"Crossnohere NL, Janse S, Janssen E, Bridges JFP. Comparing the preferences of patients and the general public for treatment outcomes in type 2 diabetes mellitus. Patient. 2021;14(1):89\u2013100.","journal-title":"Patient"},{"key":"776_CR13","first-page":"1443","volume":"9","author":"C Morillas","year":"2015","unstructured":"Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, Rodrigues J, et al. Patients\u2019 and physicians\u2019 preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Prefer Adher. 2015;9:1443\u201358.","journal-title":"Patient Prefer Adher"},{"key":"776_CR14","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2147\/PPA.S139471","volume":"11","author":"EM Janssen","year":"2017","unstructured":"Janssen EM, Longo DR, Bardsley JK, Bridges JF. Education and patient preferences for treating type 2 diabetes: a stratified discrete-choice experiment. Patient Prefer Adher. 2017;11:1729\u201336.","journal-title":"Patient Prefer Adher"},{"issue":"4","key":"776_CR15","doi-asserted-by":"publisher","first-page":"e1544","DOI":"10.1002\/hpm.2841","volume":"34","author":"J Zhu","year":"2019","unstructured":"Zhu J, Li J, Zhang Z, Li H. Patients\u2019 choice and preference for common disease diagnosis and diabetes care: a discrete choice experiment. Int J Health Plann Manag. 2019;34(4):e1544\u201355.","journal-title":"Int J Health Plann Manag"},{"key":"776_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-010942","author":"S Liu","year":"2023","unstructured":"Liu S, Liu J, Si L, Ke X, Liu L, Ren Y, et al. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey. BMJ Glob Health. 2023. https:\/\/doi.org\/10.1136\/bmjgh-2022-010942.","journal-title":"BMJ Glob Health"},{"issue":"3","key":"776_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/hex.14059","volume":"27","author":"T Xie","year":"2024","unstructured":"Xie T, Meng J, Feng Z, Gao Y, Chen T, Chen Y, et al. Assessing patient information needs for new antidiabetic medications to inform shared decision-making: a best-worst scaling experiment in China. Health Expect. 2024;27(3):e14059.","journal-title":"Health Expect"},{"issue":"3","key":"776_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40271-017-0288-y","volume":"11","author":"JA Whitty","year":"2018","unstructured":"Whitty JA, Goncalves ASO. A systematic review comparing the acceptability, validity and concordance of discrete choice experiments and best-worst scaling for eliciting preferences in healthcare. Patient. 2018;11(3):301\u201317.","journal-title":"Patient"},{"key":"776_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jocm.2013.04.004","volume":"6","author":"TN Flynn","year":"2013","unstructured":"Flynn TN, Peters TJ, Coast J. Quantifying response shift or adaptation effects in quality of life by synthesising best-worst scaling and discrete choice data. J Choice Model. 2013;6:34\u201343.","journal-title":"J Choice Model"},{"key":"776_CR20","unstructured":"Orme B. Sample size issues for conjoint analysis studies. Sequim: Sawtooth Software Technical Paper. 1998."},{"key":"776_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocm.2023.100466","author":"ALR Schuster","year":"2024","unstructured":"Schuster ALR, Crossnohere NL, Campoamor NB, Hollin IL, Bridges JFP. The rise of best-worst scaling for prioritization: a transdisciplinary literature review. J Choice Model. 2024. https:\/\/doi.org\/10.1016\/j.jocm.2023.100466.","journal-title":"J Choice Model"},{"issue":"4","key":"776_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jval.2020.10.025","volume":"24","author":"EJD Webb","year":"2021","unstructured":"Webb EJD, Meads D, Lynch Y, Judge S, Randall N, Goldbart J, et al. Attribute selection for a discrete choice experiment incorporating a best-worst scaling survey. Value Health. 2021;24(4):575\u201384.","journal-title":"Value Health"},{"issue":"9","key":"776_CR23","first-page":"1079","volume":"24","author":"Y Tao","year":"2024","unstructured":"Tao Y, Liu S, Chen Y. Optimizing the attribute selection process for stated preference study: a study based on best-worst scaling. Chin J Evid Based Med. 2024;24(9):1079\u201384.","journal-title":"Chin J Evid Based Med"},{"key":"776_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.802897","volume":"12","author":"S Liu","year":"2021","unstructured":"Liu S, Liu J, Yu Y, Si L, Tang C, Liu Z, et al. What is valued most by patients with type 2 diabetes mellitus when selecting second-line antihyperglycemic medications in China. Front Pharmacol. 2021;12:802897.","journal-title":"Front Pharmacol"},{"issue":"1","key":"776_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32(1):84\u201390.","journal-title":"Diabetes Care"},{"issue":"14","key":"776_CR26","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jama.2010.405","volume":"303","author":"OJ Phung","year":"2010","unstructured":"Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. Jama J Am Med Assoc. 2010;303(14):1410\u20138.","journal-title":"Jama J Am Med Assoc"},{"issue":"9","key":"776_CR27","doi-asserted-by":"publisher","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","volume":"154","author":"WL Bennett","year":"2011","unstructured":"Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602\u201313.","journal-title":"Ann Intern Med"},{"issue":"11","key":"776_CR28","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/dom.12942","volume":"19","author":"J Du","year":"2017","unstructured":"Du J, Liang L, Fang H, Xu F, Li W, Shen L, et al. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: results of a phase IV open-label randomized controlled study (the SMART study). Diabetes Obes Metab. 2017;19(11):1513\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"776_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/dia.2014.0188","volume":"17","author":"F Sun","year":"2015","unstructured":"Sun F, Chai S, Yu K, Quan X, Yang Z, Wu S, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17(1):35\u201342.","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"776_CR30","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23(9):2116\u201324.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"776_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"3","key":"776_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40271-023-00671-6","volume":"18","author":"DA Marshall","year":"2025","unstructured":"Marshall DA, Veldwijk J, Janssen EM, Reed SD. Stated-preference survey design and testing in health applications. Patient. 2025;18(3):187\u201397.","journal-title":"Patient"},{"key":"776_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocm.2019.100171","author":"H Aizaki","year":"2019","unstructured":"Aizaki H, Fogarty J. An R package and tutorial for case 2 best-worst scaling. J Choice Model. 2019. https:\/\/doi.org\/10.1016\/j.jocm.2019.100171.","journal-title":"J Choice Model"},{"issue":"1","key":"776_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1471-2288-8-76","volume":"8","author":"TN Flynn","year":"2008","unstructured":"Flynn TN, Louviere JJ, Peters TJ, Coast J. Estimating preferences for a dermatology consultation using best-worst scaling: comparison of various methods of analysis. BMC Med Res Methodol. 2008;8(1):76.","journal-title":"BMC Med Res Methodol"},{"key":"776_CR35","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781316136232","volume-title":"Applied choice analysis","author":"DA Hensher","year":"2015","unstructured":"Hensher DA, Rose JM, Greene WH. Applied choice analysis. Cambridge: Cambridge University Press; 2015."},{"issue":"7","key":"776_CR36","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jval.2020.02.013","volume":"23","author":"AC M\u00fchlbacher","year":"2020","unstructured":"M\u00fchlbacher AC, Sadler A, Lamprecht B, Juhnke C. Patient preferences in the treatment of hemophilia A: a best-worst scaling case 3 analysis. Value Health. 2020;23(7):862\u20139.","journal-title":"Value Health"},{"issue":"10","key":"776_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40273-022-01178-y","volume":"40","author":"S Karim","year":"2022","unstructured":"Karim S, Craig BM, Vass C, Groothuis-Oudshoorn CGM. Current practices for accounting for preference heterogeneity in health-related discrete choice experiments: a systematic review. Pharmacoeconomics. 2022;40(10):943\u201356.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"776_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10705510701575396","volume":"14","author":"KL Nylund","year":"2007","unstructured":"Nylund KL, Tihomir A, Muth\u00e9n BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535\u201369.","journal-title":"Struct Equ Model"},{"key":"776_CR39","unstructured":"Law EH, Harrington R. A primer on latent class analysis value & outcomes spotlight. 2016. p. 18\u20139."},{"issue":"2","key":"776_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40271-017-0282-4","volume":"11","author":"CM Vass","year":"2018","unstructured":"Vass CM, Wright S, Burton M, Payne K. Scale heterogeneity in healthcare discrete choice experiments: a primer. Patient. 2018;11(2):167\u201373.","journal-title":"Patient"},{"issue":"3","key":"776_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/1536867X1301300312","volume":"13","author":"D Pacifico","year":"2013","unstructured":"Pacifico D, Yoo HI. Lclogit: a Stata command for fitting latent-class conditional logit models via the expectation-maximization algorithm. Stata J. 2013;13(3):625\u201339.","journal-title":"Stata J"},{"key":"776_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodqual.2022.104755","author":"J Rolfe","year":"2023","unstructured":"Rolfe J, Rajapaksa D, De Valck J, Star M. Will greenhouse concerns impact meat consumption? Best-worst scaling analysis of Australian consumers. Food Qual Prefer. 2023. https:\/\/doi.org\/10.1016\/j.foodqual.2022.104755.","journal-title":"Food Qual Prefer"},{"key":"776_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1017\/CBO9781107337855.004","volume-title":"Best-worst scaling: theory, methods and applications","author":"JJ Louviere","year":"2015","unstructured":"Louviere JJ, Flynn TN, Marley AAJ. The BWS profile case. In: Louviere JJ, Flynn TN, Marley AAJ, editors. Best-worst scaling: theory, methods and applications. Cambridge: Cambridge University Press; 2015. p. 56\u201388."},{"issue":"1","key":"776_CR44","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jhealeco.2006.04.002","volume":"26","author":"TN Flynn","year":"2007","unstructured":"Flynn TN, Louviere JJ, Peters TJ, Coast J. Best-worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171\u201389.","journal-title":"J Health Econ"},{"issue":"3","key":"776_CR45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ijresmar.2012.10.002","volume":"30","author":"J Louviere","year":"2013","unstructured":"Louviere J, Lings I, Islam T, Gudergan S, Flynn T. An introduction to the application of (case 1) best-worst scaling in marketing research. Int J Res Mark. 2013;30(3):292\u2013303.","journal-title":"Int J Res Mark"},{"issue":"6","key":"776_CR46","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jmp.2005.05.003","volume":"49","author":"AAJ Marley","year":"2005","unstructured":"Marley AAJ, Louviere JJ. Some probabilistic models of best, worst, and best-worst choices. J Math Psychol. 2005;49(6):464\u201380.","journal-title":"J Math Psychol"},{"issue":"3","key":"776_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1586\/erp.10.29","volume":"10","author":"TN Flynn","year":"2010","unstructured":"Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best-worst scaling. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):259\u201367.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"776_CR48","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40271-024-00694-7","volume":"17","author":"L-H Chuang","year":"2024","unstructured":"Chuang L-H, Zhang H, Hong T, Xie S. Evaluating the preferences and willingness-to-pay for oral antidiabetic drugs among patients with type 2 diabetes mellitus in China: a discrete choice experiment. Patient Patient-Centered Outcomes Res. 2024;17(5):565\u201374.","journal-title":"Patient Patient-Centered Outcomes Res"},{"issue":"7","key":"776_CR49","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1089\/thy.2019.0592","volume":"30","author":"AM Sawka","year":"2020","unstructured":"Sawka AM, Ghai S, Yoannidis T, Rotstein L, Gullane PJ, Gilbert RW, et al. A prospective mixed-methods study of decision-making on surgery or active surveillance for low-risk papillary thyroid cancer. Thyroid. 2020;30(7):999\u20131007.","journal-title":"Thyroid"},{"issue":"1","key":"776_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pcd.2020.05.004","volume":"15","author":"S Seidu","year":"2021","unstructured":"Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, et al. A disease state approach to the pharmacological management of type 2 diabetes in primary care: a position statement by Primary Care Diabetes Europe. Prim Care Diabetes. 2021;15(1):31\u201351.","journal-title":"Prim Care Diabetes"},{"issue":"7","key":"776_CR51","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.healthpol.2017.05.001","volume":"121","author":"M Tinelli","year":"2017","unstructured":"Tinelli M, Petrou P, Samoutis G, Traynor V, Olympios G, McGuire A. Implementing shared-decision-making for diabetes care across country settings: what really matters to people? Health Policy. 2017;121(7):786\u201392.","journal-title":"Health Policy"},{"issue":"11","key":"776_CR52","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"2","key":"776_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jval.2022.12.004","volume":"26","author":"JFP Bridges","year":"2023","unstructured":"Bridges JFP, de Bekker-Grob EW, Hauber B, Heidenreich S, Janssen E, Bast A, et al. A roadmap for increasing the usefulness and impact of patient-preference studies in decision making in health: a good practices report of an ISPOR task force. Value Health. 2023;26(2):153\u201362.","journal-title":"Value Health"},{"issue":"6","key":"776_CR54","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40271-015-0115-2","volume":"8","author":"BH Salampessy","year":"2015","unstructured":"Salampessy BH, Veldwijk J, Jantine Schuit A, van den Brekel-Dijkstra K, Neslo RE, de Wit GA, et al. The predictive value of discrete choice experiments in public health: an exploratory application. Patient. 2015;8(6):521\u20139.","journal-title":"Patient"},{"key":"776_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112736","volume":"246","author":"EW de Bekker-Grob","year":"2020","unstructured":"de Bekker-Grob EW, Donkers B, Bliemer MCJ, Veldwijk J, Swait JD. Can healthcare choice be predicted using stated preference data? Soc Sci Med. 2020;246:112736.","journal-title":"Soc Sci Med"},{"issue":"5","key":"776_CR56","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/hec.4246","volume":"30","author":"K de Corte","year":"2021","unstructured":"de Corte K, Cairns J, Grieve R. Stated versus revealed preferences: an approach to reduce bias. Health Econ. 2021;30(5):1095\u2013123.","journal-title":"Health Econ"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00776-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:03:23Z","timestamp":1772017403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00776-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00776-0","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Dai Lian: writing\u2014original draft, visualization, formal analysis, software. Jing Liu: investigation, validation, writing\u2014review and editing. Yan Wei: investigation, validation, writing\u2014review and editing. Yi Yang: investigation, validation, writing\u2014review and editing. Yanfeng Ren: investigation, validation, writing\u2014review and editing. Shiyi Bao: investigation, validation, writing\u2014review and editing. Liu Liu: investigation, validation, writing\u2014review and editing. Shimeng Liu: investigation,\u00a0formal analysis, writing\u2014original draft, writing\u2014review and editing, project administration, supervision, conceptualization. Yingyao Chen: investigation,\u00a0writing\u2014review and editing, supervision, resources, project administration, funding acquisition, conceptualization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The study was performed according to the guidelines of the Declaration of Helsinki. The ethics review board of the School of Public Health at Fudan University approved this study (Reference No. IRB# 2021-07-0911). All participants signed informed consent forms.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Data are available on request. The data sets used and analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}